



# **Dysregulation of cell-type specific long ncRNA in the ileum of treatment naïve early onset Crohn Disease**

Yael Haberman, MD, PhD

Sheba Medical Center, Israel

On behalf of the Crohn's & Colitis Foundation (CCF)-sponsored RISK study

Vienna, Feb, 2018




## **Disclosure of Conflicts of Interest:**

Conflict of interest :

Grant funding for this work included ECCO, CCF, ISF, I-Core, and The Leona M. and Harry B. Helmsley Charitable Trust.

# lncRNA definitions and known functions


- LncRNA are diverse class of non-protein coding transcripts longer than 200 nucleotides.
- LncRNA are key regulators of gene transcription.



- LncRNAs dynamically regulate the immune system (i.e. Morrbid, Lethe, Lnc-DC) .
- Only a few studies to date have focused on lncRNA in human gut pathogenesis, and there have been no studies of the ileum of patients with Crohn Disease.

# Hypothesis and aim

We defined core inflammatory and metabolic ileal gene signature in treatment naïve pediatric Crohn Disease (CD).



Haberman et al JCI 2014

**Our hypothesis** is that **lncRNA** will have **tissue specific regulatory** role in **tuning the inflammatory cascade and epithelial functions** in **CD pathogenesis**


We extend our analyses to define a more comprehensive view of CD pathogenesis that includes lncRNA.

# Widespread dysregulation of 459 lncRNA in the ileum of treatment naïve pediatric iCD (L1, L3) patients


## Discovery

	Ctl (n=30)	CD (n=111)
Age (mean, SD)	11.2(3)	11.9(3)
Male (%)	60%	61%
PCDAI mild (11-30)	-	39%
PCDAI mod-sev (>=31)	-	53%

## Discovery cohort – using only lncRNA



## Discovery cohort





lncRNAs can be utilized to correctly classify disease or healthy states

# Prioritizing the down-regulated lncRNA based on fold change and by using “Guilt-by-association” co expression: top down-regulated *CDKN2B-AS1* (*ANRIL*) & *HNF4A-AS1* lncRNAs show strong co-expression with an epithelial metabolic signature.

**A** Top 15 down-regulated lncRNA genes

Gene	FC (CD) vs. Co-expression	Co-expression
RP11-249C24.11	-16.2	1
RP11-347E10.1	-14.5	105
RP11-64D22.5	-8.5	6
FOXD1-AS1	-8.1	1
LINC01595	-7.9	1
RP11-132E11.2	-7.3	112
RP11-116D2.1	-7.0	25
<b>CDKN2B-AS1</b>	<b>-6.9</b>	<b>365</b>
RP11-245G13.2	-6.7	1
<b>HNF4A-AS1</b>	<b>-6.2</b>	<b>1</b>
RP11-798K3.2	-5.7	153
RP11-680F8.1	-5.6	73
RP3-368B9.2	-5.6	2
RP11-689K5.3	-5.5	1



CDKN2B-AS1 “Guilt-by-association” network


# Prioritizing the up-regulated lncRNA based on fold change and by using “Guilt-by-association” co expression: the up-regulated LINC01272 is associated with a strong granulocytes signature

A


Top15 up-regulated differentially expressed lncRNA genes

Top 15 up-regulated	FC [iCD] vs. [Ctl]	Co-expression
CTB-61M7.2	12.8	19
RP11-598F7.3	11.5	1
LUCAT1	10.8	17
<b>LINC01272</b>	<b>9.3</b>	<b>116</b>
RP11-290L1.3	7.1	1
LINC00694	6.4	1
CTC-490G23.2	5.9	1
RP11-701P16.5	5.8	1
LINC01235	5.2	1
RP11-638I2.8	4.9	1
FAM225A	4.4	46
RP11-44K6.2	4.4	1
RP11-20G13.2	4.2	1
RP11-536O18.1	3.7	1
CTA-384D8.35	3.6	1

B



C




LINC01272 “Guilt-by-association” network


# Conclusions and Future Considerations



Differential expression using RNAseq and GENCODE/Ensembl annotation



Prioritization of lncRNA based on fold change and co-expression networks



We plan to elucidate their molecular mechanisms to provide more comprehensive insights into CD pathogenesis and ultimately lead to novel tissue specific therapies





## Acknowledgments

### Sheba Medical center

Lab members

- Tzipi Braun
- Ayelet Di segni\*
- Gilat Efroni
- Marina BenShoshan\*
- Nurit Nachum
- Katia Sosnovski

### Collaborators:

Dr. Lee Denson (CCHMC)

RISK cohort site investigators

Sheba pathology lab

## Funding



European Crohn's and Colitis Organisation



THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST

